EBMT 2017

26–29 March 2017 | Marseille, France

The 43rd European Bone Marrow Transplant Congress (EBMT) Annual Meeting will be held in Marseilles, France on March 26-29, 2017.

This will also be the 33rd EBMT Nurses Group meeting, 16th EBMT Data Management Group Meeting, 9th EBMT Quality Management Group Meeting, 2nd EBMT Pharmacist Day, and 11th EBMT Patient & Family Day.

EBMT 2017

26–29 March 2017 | Marseille, France

The 43rd European Bone Marrow Transplant Congress (EBMT) Annual Meeting will be held in Marseilles, France on March 26-29, 2017.

This will also be the 33rd EBMT Nurses Group meeting, 16th EBMT Data Management Group Meeting, 9th EBMT Quality Management Group Meeting, 2nd EBMT Pharmacist Day, and 11th EBMT Patient & Family Day.

Concerns about using social media in oncology 4:58
Concerns about using social media in oncology
Naveen Pemmaraju • 26 Mar 2017
Predicting and preventing clonal evolution in multiple myeloma 1:47
Predicting and preventing clonal evolution in multiple myeloma
Irene Ghobrial • 26 Mar 2017
Only the beginning of precision medicine and multiple myeloma. 1:24
Only the beginning of precision medicine and multiple myeloma.
Irene Ghobrial • 26 Mar 2017
Autologous stem cell transplantations: BEAM or BEAC? 2:05
Autologous stem cell transplantations: BEAM or BEAC?
Stephen Robinson • 26 Mar 2017
Updates on treatment methods for Hodgkin Lymphoma 2:00
Updates on treatment methods for Hodgkin Lymphoma
Stephen Robinson • 26 Mar 2017
Cellular therapy: a key part of EBMT 2017 1:26
Cellular therapy: a key part of EBMT 2017
Nicolaus Kröger • 26 Mar 2017
Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome 3:14
Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome
Maria Teresa Voso • 26 Mar 2017
Allogeneic transplant is not the quintessential treatment for ALL anymore! 4:01
Allogeneic transplant is not the quintessential treatment for ALL anymore!
Sebastian Giebel • 26 Mar 2017
Treatment methods in mantle cell lymphoma 1:24
Treatment methods in mantle cell lymphoma
Stephen Robinson • 26 Mar 2017
What are the differences in health technology assessment (HTA) across Europe? 3:26
What are the differences in health technology assessment (HTA) across Europe?
Jean-Luc Harousseau • 28 Mar 2017
How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)? 6:43
How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)?
Nathaniel Treister • 27 Mar 2017
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)? 2:36
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?
John Gribben • 26 Mar 2017
Can the cytomegalovirus be predicted by ELISpot assays? 2:40
Can the cytomegalovirus be predicted by ELISpot assays?
Roy Chemaly • 26 Mar 2017
Highlights from the EBMT 2017 cell therapy day 2:19
Highlights from the EBMT 2017 cell therapy day
Christian Chabannon • 28 Mar 2017
Waldenström’s macroglobulinemia: Treatment methods and clonal evolution 1:50
Waldenström’s macroglobulinemia: Treatment methods and clonal evolution
Irene Ghobrial • 27 Mar 2017
Is double autologous transplantation in multiple myeloma superior in the age of new agents? 3:44
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau • 28 Mar 2017
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals